- Home
- AIFA vs PASG Comparison
AIFA vs PASG Comparison
Compare AIFA & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.90
N/A
Current Price
$4.59
Company Overview
Basic Information| Metric | AIFA | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 14.8M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AIFA | PASG |
|---|---|---|
| Price | $2.90 | $4.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 389.0K | 23.0K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,655,039.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.50 | N/A |
| 52 Week Low | $1.52 | $3.29 |
| 52 Week High | $3.45 | $20.00 |
Technical Indicators
Market Signals| Indicator | AIFA | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 45.74 |
| Support Level | $1.62 | $4.25 |
| Resistance Level | $3.45 | $4.75 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 79.97 | 60.00 |
Price Performance
Historical Comparison AIFA
PASG
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.